Business Context and Reporting Period
This Form 8-K Current Report was filed by Halozyme Therapeutics, Inc. on February 3, 2022, covering events that occurred on February 2, 2022. The filing addresses significant changes in the Company's executive leadership, specifically within the finance function.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel changes and compensation arrangements.
Material Changes
- Departure of CFO: Elaine Sun stepped down as Senior Vice President and Chief Financial Officer effective immediately on February 2, 2022, to pursue another opportunity.
- Appointment of New CFO: Nicole LaBrosse was appointed as Senior Vice President and Chief Financial Officer effective immediately on February 2, 2022.
- Separation Agreement: The Company intends to enter into a separation agreement with Ms. Sun providing benefits consistent with those disclosed in a prior Form 8-K filed on December 13, 2018.
Management Commentary and Compensation
Ms. LaBrosse has been with the Company since June 2015, previously serving as Vice President, Finance and Accounting (since January 2020), Executive Director, Controller, and Senior Director, Financial Reporting. Her compensation package includes:
- Base Salary: $485,500 annually.
- Bonus Target: 45% of base salary for 2022.
- Long-Term Incentives: Eligible for awards in accordance with the Compensation Committee's equity award grant practices.
The filing states there are no family relationships between Ms. LaBrosse and any director or executive officer, and she holds no material interest in any transaction involving the Company.
Investor Verification Checklist
- Verify the specific terms of the separation agreement for Elaine Sun by reviewing the Form 8-K filed on December 13, 2018.
- Confirm the transition timeline for financial reporting responsibilities between the outgoing and incoming CFO.
- Review the Company's executive incentive plan details to understand the structure of the long-term equity awards mentioned for Ms. LaBrosse.